Nektar Therapeutics (NKTR) CEO Howard Robin Sells $612K of Stock

Howard Robin, President and CEO of Nektar Therapeutics, sold 10,000 shares of the company on June 17, 2026. The shares were sold at an average price of $61.19, totaling about $611,880. This transaction was part of a planned sale.

Insider Buying and Selling at Nektar Therapeutics

Howard Robin has been active in selling shares of Nektar Therapeutics, with multiple transactions over recent months. On June 16, 2026, he also sold another 10,000 shares at an average price of $60.32. Earlier, on May 19, 2026, he sold 444 shares at $65.51. Jonathan Zalevsky, the Chief R&D Officer, sold 5,538 shares on June 15, 2026, at $60.71, also under a planned sale.

Other Institutional Activity in Nektar Therapeutics

Several institutional investors have recently adjusted their positions in Nektar Therapeutics. FMR LLC boosted its holdings by 4,202,059 shares, bringing its total to 4,303,188 shares valued at approximately $309.6 million. BVF INC/IL increased its stake by 1,000,000 shares, ending with 2,559,595 shares worth about $184.2 million. TWO SEAS CAPITAL LP added 1,213,993 shares, totaling 1,959,178 shares valued at approximately $141.0 million. VANGUARD CAPITAL MANAGEMENT LLC now holds 1,197,055 shares valued at $86.1 million after adding all its shares in the recent period.

Nektar Therapeutics Stock Down 9.1%

Shares of Nektar Therapeutics (NasdaqCM:NKTR) traded around $60.98. The company's market cap is about $2.06 billion. It has a forward P/E ratio that isn't meaningful as the company is not currently profitable. Nektar's stock has ranged from a 52-week low of $8.35 to a high of $109.00. The 50-day moving average is $74.00, while the 200-day moving average is $60.74. The company maintains a strong liquidity position with a current ratio of 10.207 and a quick ratio of 9.916.

Recent Earnings

Nektar Therapeutics reported revenue of $55.63 million with a slight growth of 3.8%. However, the company is still facing challenges with a negative net margin of -284.18% and a return on equity of -53.6%. The next earnings report is scheduled for August 6, 2026.

Analysts Set New Price Targets

On May 11, 2026, Wedbush maintained a 'hold' rating with an $80.00 price target. Piper Sandler, on May 8, 2026, reiterated a 'buy' rating with a target of $192.00. Citigroup maintained its 'buy' rating with a $151.00 target on April 21, 2026. The consensus among analysts is a 'buy' rating with an average price target of $153.25 from eight analysts.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California. It focuses on developing innovative medicines in the field of immunotherapy. The company is working on several projects, including treatments for autoimmune disorders and cancer. Nektar collaborates with major pharmaceutical companies such as AstraZeneca and Pfizer. With a workforce of 63 employees, Nektar is led by CEO Howard Robin.

Bottom Line

Insider sales, like those by Howard Robin, are often scrutinized by investors to gauge executive confidence. These transactions are part of routine planned sales and do not necessarily signal a lack of confidence in the company. Meanwhile, institutional activity shows that major investors are increasing their stakes, indicating continued interest in Nektar's potential. Remember, insider and institutional activities are historical and may not reflect current sentiment.